Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

23.96
+0.27001.14%
Volume:2.40M
Turnover:56.91M
Market Cap:2.69B
PE:-15.59
High:24.14
Open:23.61
Low:23.39
Close:23.69
52wk High:81.73
52wk Low:18.92
Shares:112.44M
Float Shares:109.98M
Volume Ratio:0.66
T/O Rate:2.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5368
EPS(LYR):-1.0085
ROE:-19.99%
ROA:-14.99%
PB:3.39
PE(LYR):-23.76

Loading ...

Viking Therapeutics Shares Down 3.8% After Rival Eli Lilly's Glp-1 Pill Helps Cut Body Weight in Late Stage Study of Diabetes Patients

THOMSON REUTERS
·
Aug 26

Goldman Sachs Reviews Viking Therapeutics (VKTX.US) Oral Drug VK2735 Trial Results: Significant Efficacy but Questionable Tolerability, Better Suited for Weight Maintenance

Stock News
·
Aug 21

Stock Track | Viking Therapeutics Soars 5.05% Despite Mixed Results from Obesity Drug Trial

Stock Track
·
Aug 20

Oral Weight Loss Drug "Crashes"! Viking Therapeutics Stock Plunges 42% as Short Sellers Reap $521 Million Overnight

Stock News
·
Aug 20

Small U.S. Stocks Close Mixed As Kyivstar Group Leads, Viking Therapeutics Lags

Dow Jones
·
Aug 20

Viking's Oral Weight-Loss Drug Still Shows Promise -- Market Talk

Dow Jones
·
Aug 20

Viking Therapeutics Price Target Maintained With a $102.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 19

This Weight-Loss Stock Fell 40%. It Lowers the Risks for Eli Lilly and Novo Nordisk. -- Barrons.com

Dow Jones
·
Aug 19

Viking Therapeutics Shares Set for Biggest One-Day Drop on Record, Last Down 38.9%

THOMSON REUTERS
·
Aug 19

Stock Track | Viking Therapeutics Plummets 40.62% Despite Positive Phase 2 Results for Obesity Drug

Stock Track
·
Aug 19

Viking Therapeutics Shares Fall 40.4% After Mid-Stage Trial Data for Experimental Obesity Drug Shows Higher Patient Exits

THOMSON REUTERS
·
Aug 19

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

Benzinga_recent_news
·
Aug 19

Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday

MT Newswires Live
·
Aug 19

Viking Therapeutics Stock Plunges 33% After Disappointing Weight-Loss Pill Data

Dow Jones
·
Aug 19

Viking Therapeutics Shares Fall Pre-Bell After Release of Phase 2 Obesity Trial Results

MT Newswires Live
·
Aug 19

BUZZ-Viking Therapeutics' oral obesity drug meets mid-stage study goal, shares fall

Reuters
·
Aug 19

Viking Therapeutics Shares Down 28.8% Premarket After Co Reports Mid-Stage Trial Data for Experimental Obesity Drug

THOMSON REUTERS
·
Aug 19

Stock Track | Viking Therapeutics Plunges 31.91% Pre-market Despite Positive Weight-Loss Pill Trial Results

Stock Track
·
Aug 19

Stock Track | Viking Therapeutics Plunges 31.91% Pre-market Despite Positive Weight-Loss Drug Results

Stock Track
·
Aug 19